

Randomised controlled trial of dialysate cooling for preservation of cognitive function in haemodialysis

Submission date 23/04/2026	Recruitment status Recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 07/05/2026	Overall study status Ongoing	☐ Statistical analysis plan
		☐ Results
Last Edited 07/05/2026	Condition category Mental and Behavioural Disorders	☐ Individual participant data
		☒ Record updated in last year

Plain English summary of protocol

Background and study aims

Thinking and memory problems affect working memory and people's abilities to remember and perform daily life tasks. Thinking and memory problems are common in people receiving haemodialysis. Haemodialysis can affect blood pressure and the brain blood supply, which may lead to worsening in thinking and memory abilities. There are currently no treatments to protect against thinking and memory problems in people receiving haemodialysis. Dialysate cooling is a method of reducing the temperature of the fluid used in the haemodialysis machine and has been shown to have positive effects on blood pressure in other studies. This study will explore whether dropping the temperature of dialysis fluid by 0.5 degrees (dialysate cooling) can preserve thinking and memory functions in people receiving haemodialysis.

Who can participate?

Patients over the age of 18 years who are receiving haemodialysis

What does the study involve?

The study involves participants undergoing their usual haemodialysis. Some participants will be randomly allocated to have dialysis at a cooler temperature (0.5 degrees lower than body temperature). At baseline and after 1 year, all participants will complete a number of questionnaires and cognitive assessments

What are the possible benefits and risks of participating?

Dialysate cooling is safe and no riskier than usual dialysis treatment. Some patients do report coldness or feeling cold during dialysis treatment.

This study will help us answer the question of whether dropping the temperature of the dialysis fluid by 0.5 degrees below the person's body temperature is the way to preserve thinking and memory functions in people receiving haemodialysis.

Where is the study run from?

Derby Clinical Trials Support Unit (UK)

When is the study starting and how long is it expected to run for?
April 2026 to October 2027

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?
Derby Clinical Trials Unit, uhdb.coolhdstudy@nhs.net

Contact information

Type(s)
Scientific

Contact name
Dr Daniel Davis

Contact details
422 Medical School, Derby Clinical Trials Support Unit, Royal Derby Hospital
Derby
United Kingdom
DE22 3DT
+44 (0)7472910392
daniel.davis6@nhs.net

Type(s)
Principal investigator

Contact name
Dr Mohamed Tarek Eldenhi

ORCID ID
<https://orcid.org/0000-0003-1681-9048>

Contact details
School of Medicine, Royal Derby Hospital
Derby
United Kingdom
DE22 3DT
+44 (0)7867533453
tarek.eldehni@nhs.net

Type(s)
Public, Scientific

Contact name
None Derby Clinical Trials Support Unit

Contact details

422 Medical School, Royal Derby Hospital
Derby
United Kingdom
DE2 23DT
+44 (0)1332340131
uhdb.coolhdstudy@nhs.net

Additional identifiers

Integrated Research Application System (IRAS)
345755

Central Portfolio Management System (CPMS)
63214

National Institute for Health and Care Research (NIHR)
208855

Study information

Scientific Title

Randomised controlled trial of dialysate cooling for the preservation of cognitive function in haemodialysis patients (COOL HD)

Acronym

COOL HD

Study objectives

This study aims to answer the question of whether lowering the dialysis fluid temperature by 0.5 degrees below the person's body temperature leads to preservation of thinking and memory functions in people receiving Haemodialysis.

The study will measure secondary outcomes such quality of life, hospitalisation episodes and length of these hospital admissions, the degree of frailty and any adverse events related to cooling such as feeling cold and heart and stroke events.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 19/02/2026, Yorkshire & The Humber - Leeds East Research Ethics Committee (N/A, N/A, N/A, United Kingdom; N/A; leedseast.rec@hra.nhs.uk), ref: 26/YH/0023

Primary study design

Interventional

Study design

Randomized controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cognitive function in haemodialysis patients

Interventions

This is a randomised study, meaning participants are assigned by chance to one of two groups for 1 year:

1. Dialysis fluid is set at 37°C (normal body temperature)
2. Dialysis fluid is set at 0.5°C below the person's body temperature.

Participants will have two main study visits at the start of the study and 1 year later

At both visits, trained researchers will assess:

1. Thinking and memory (using simple tests)
2. Frailty (how physically vulnerable someone is)
3. Quality of life (how people feel day-to-day)

These assessments will be done before a dialysis session. At the start, researchers will also record:

1. Age, sex, ethnicity
2. Height, weight, blood pressure
3. Dialysis details and medical history
4. Current medications
5. Routine blood test results (already taken as part of normal care)

During the year dialysis temperature will be checked monthly; blood results, hospital admissions, and heart-related events will be reviewed every 3 months. Safety will be monitored throughout the study.

Intervention Type

Other

Primary outcome(s)

1. Working memory measured using the Letter Number Sequencing (LNS) test at 1 year after randomisation

Key secondary outcome(s)

1. Other cognitive domains: processing speed, inhibition, attention, perception and general cognition and memory measured using Digit symbol matching task, Flanker Test and Letter Number Sequence Task at baseline and 12 months
2. Clinical outcomes, namely, number and length of hospitalisation episodes and frailty score measured by the clinical frailty score at baseline and 12 months
3. Quality of life measured by the Short Form Health Survey Questionnaire (SF-36) at baseline and 12 months
4. Adverse events and serious adverse events related to intervention, cardiovascular events and cerebral ischaemic events recorded at baseline, 3, 6, 9 and 12 months

Completion date

31/10/2027

Eligibility

Key inclusion criteria

1. The participant is receiving maintenance in-centre haemodialysis
2. Over 18 years of age at time of consent
3. The participant is able and willing to provide written informed consent

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 Years

Upper age limit

100 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Participants with confirmed diagnosis of dementia
2. Participants who lack capacity to consent
3. Participants having dialysis less than three times a week
4. Pregnant participants

Date of first enrolment

01/04/2026

Date of final enrolment

01/10/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

University Hospitals of Derby and Burton NHS Foundation Trust
Royal Derby Hospital
Uttoxeter Road

Derby
England
DE22 3NE

Study participating centre
Nottingham University Hospitals NHS Trust
Trust Headquarters
Queens Medical Centre
Derby Road
Nottingham
England
NG7 2UH

Study participating centre
University Hospitals of Leicester NHS Trust
Leicester Royal Infirmary
Infirmary Square
Leicester
England
LE1 5WW

Sponsor information

Organisation
University Hospitals of Derby and Burton NHS Foundation Trust

ROR
<https://ror.org/04w8sxm43>

Funder(s)

Funder type
Government

Funder Name
National Institute for Health and Care Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Data sharing statement to be made available at a later date